FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202192556> ?p ?o ?g. }

• W3202192556 endingPage "73" @default.
• W3202192556 startingPage "65" @default.
• W3202192556 abstract "In recent times, the US-FDA approved istradefylline and opicapone as an adjunct to levodopa/carbidopa for managing the off episodes in Parkinson's disease.Current meta-analysis was performed to determine the safety and efficacy of these drugs in the management of off episodes and to recognize which among them would provide therapeutic benefits clinically.A thorough literature search was performed through the Cochrane Library, PubMed, and clinicaltrials.gov for a period from January 2003 to October 2020, with the following keywords: Istradefylline, KW-6002, opicapone, BIA 9-1067, and Parkinson's disease. Those randomized, double-blind placebo/active comparator-controlled trials that analyzed the efficacy and safety of istradefylline and opicapone and that were published in the English language were included. In this analysis, the outcomes focused on the least square mean change in off time and Unified Parkinson's Disability Rating Scale (UPDRS) III score from baseline to the end of the study, and the incidence of treatment-emergent adverse events (TEAEs) and dyskinesia.Both drugs have shown significant reduction in off time duration (mean difference [MD] = -0.70; 95% CI [-1.11, -0.30]; P < 0.001 for istradefylline and MD = -0.85; 95% CI [-1.09, -0.61]; P < .001 for opicapone). Istradefylline showed significant improvement in UPDRS III (MD = -1.56; 95% CI [-2.71, -0.40]; P < .008), but the same was not observed with opicapone (MD = -0.63; 95% CI [-1.42, -0.15]; P < .12). The incidence of TEAEs and dyskinesia reportedly were higher in the intervention group rather than with the placebo, (risk ratio RR =1.11, 95% CI [1.02,1.20] for istradefylline and RR =1.12, 95% CI [1.00,1.25] for opicapone, and for dyskinesia particularly, the incidence was higher with opicapone as compared to istradefylline (RR = 3.47, 95% CI [2.17, 5.57], and RR = 1.77, 95% CI [1.29, 2.44], respectively).Both drugs were comparable in efficacy; however, istradefylline seemed to be better in reducing the UPDRS III score. Although the incidence of TEAEs and dyskinesia were higher with both the drugs, the incidence of dyskinesia was more in the opicapone group." @default.
• W3202192556 created "2021-10-11" @default.
• W3202192556 creator A5025212128 @default.
• W3202192556 creator A5055174404 @default.
• W3202192556 creator A5074343447 @default.
• W3202192556 creator A5086742042 @default.
• W3202192556 date "2021-01-01" @default.
• W3202192556 modified "2023-10-18" @default.
• W3202192556 title "Istradefylline Versus Opicapone for “Off” Episodes in Parkinson’s Disease: A Systematic Review and Meta-Analysis" @default.
• W3202192556 cites W1493115321 @default.
• W3202192556 cites W2008560062 @default.
• W3202192556 cites W2009775147 @default.
• W3202192556 cites W2039472685 @default.
• W3202192556 cites W2048127794 @default.
• W3202192556 cites W2070912312 @default.
• W3202192556 cites W2088277236 @default.
• W3202192556 cites W2115639304 @default.
• W3202192556 cites W2126930838 @default.
• W3202192556 cites W2146659986 @default.
• W3202192556 cites W2161374186 @default.
• W3202192556 cites W2218385786 @default.
• W3202192556 cites W2464977649 @default.
• W3202192556 cites W2562545595 @default.
• W3202192556 cites W2616834563 @default.
• W3202192556 cites W2773023850 @default.
• W3202192556 cites W2775013655 @default.
• W3202192556 cites W2796177642 @default.
• W3202192556 cites W2892998861 @default.
• W3202192556 cites W2901519529 @default.
• W3202192556 cites W2921691260 @default.
• W3202192556 cites W3006012411 @default.
• W3202192556 cites W3011440063 @default.
• W3202192556 cites W3023756899 @default.
• W3202192556 cites W3093016881 @default.
• W3202192556 cites W3099102377 @default.
• W3202192556 cites W4211217223 @default.
• W3202192556 cites W4236290827 @default.
• W3202192556 cites W4241279990 @default.
• W3202192556 cites W2803391869 @default.
• W3202192556 doi "https://doi.org/10.1177/09727531211046362" @default.
• W3202192556 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8558978" @default.
• W3202192556 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34733056" @default.
• W3202192556 hasPublicationYear "2021" @default.
• W3202192556 type Work @default.
• W3202192556 sameAs 3202192556 @default.
• W3202192556 citedByCount "3" @default.
• W3202192556 countsByYear W32021925562022 @default.
• W3202192556 crossrefType "journal-article" @default.
• W3202192556 hasAuthorship W3202192556A5025212128 @default.
• W3202192556 hasAuthorship W3202192556A5055174404 @default.
• W3202192556 hasAuthorship W3202192556A5074343447 @default.
• W3202192556 hasAuthorship W3202192556A5086742042 @default.
• W3202192556 hasBestOaLocation W32021925561 @default.
• W3202192556 hasConcept C120665830 @default.
• W3202192556 hasConcept C121332964 @default.
• W3202192556 hasConcept C126322002 @default.
• W3202192556 hasConcept C142724271 @default.
• W3202192556 hasConcept C168563851 @default.
• W3202192556 hasConcept C1862650 @default.
• W3202192556 hasConcept C197934379 @default.
• W3202192556 hasConcept C204787440 @default.
• W3202192556 hasConcept C27081682 @default.
• W3202192556 hasConcept C2776478404 @default.
• W3202192556 hasConcept C2779134260 @default.
• W3202192556 hasConcept C2779734285 @default.
• W3202192556 hasConcept C2780304432 @default.
• W3202192556 hasConcept C2780405171 @default.
• W3202192556 hasConcept C61511704 @default.
• W3202192556 hasConcept C71924100 @default.
• W3202192556 hasConcept C95190672 @default.
• W3202192556 hasConceptScore W3202192556C120665830 @default.
• W3202192556 hasConceptScore W3202192556C121332964 @default.
• W3202192556 hasConceptScore W3202192556C126322002 @default.
• W3202192556 hasConceptScore W3202192556C142724271 @default.
• W3202192556 hasConceptScore W3202192556C168563851 @default.
• W3202192556 hasConceptScore W3202192556C1862650 @default.
• W3202192556 hasConceptScore W3202192556C197934379 @default.
• W3202192556 hasConceptScore W3202192556C204787440 @default.
• W3202192556 hasConceptScore W3202192556C27081682 @default.
• W3202192556 hasConceptScore W3202192556C2776478404 @default.
• W3202192556 hasConceptScore W3202192556C2779134260 @default.
• W3202192556 hasConceptScore W3202192556C2779734285 @default.
• W3202192556 hasConceptScore W3202192556C2780304432 @default.
• W3202192556 hasConceptScore W3202192556C2780405171 @default.
• W3202192556 hasConceptScore W3202192556C61511704 @default.
• W3202192556 hasConceptScore W3202192556C71924100 @default.
• W3202192556 hasConceptScore W3202192556C95190672 @default.
• W3202192556 hasIssue "1-2" @default.
• W3202192556 hasLocation W32021925561 @default.
• W3202192556 hasLocation W32021925562 @default.
• W3202192556 hasLocation W32021925563 @default.
• W3202192556 hasLocation W32021925564 @default.
• W3202192556 hasOpenAccess W3202192556 @default.
• W3202192556 hasPrimaryLocation W32021925561 @default.
• W3202192556 hasRelatedWork W2231018250 @default.
• W3202192556 hasRelatedWork W2317729153 @default.
• W3202192556 hasRelatedWork W2330870245 @default.
• W3202192556 hasRelatedWork W2374685850 @default.

• next